Personalised indication of augmentation therapy for emphysema associated with severe alpha-1 antitrypsin deficiency: a case series
Therapeutic Advances in Respiratory Disease · 2024-01 · 18
DOI: 10.1177/17534666241271917 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 12.08.2024. Verfasst von Cristina Aljama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER …. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin, alpha 1-Antitrypsin Deficiency, Pulmonary Emphysema. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Severe alpha-1 antitrypsin deficiency (AATD) is associated with an increased risk of emphysema. However, the clinical manifestations are very heterogeneous, and an individual prognosis is very difficult to establish. Intravenous augmentation therapy with alpha-1 antitrypsin (AAT) from pooled blood donors is the only specific treatment available, but it requires weekly or biweekly administration for life. Several guidelines provide the indication criteria for the initiation of AAT augmentation therapy. However, in clinical practice, there are situations in which the decision as to when to start treatment becomes uncertain and some studies have shown great variability in the indication of this treatment even among specialists. The usual dilemma is between initiating augmentation therapy in individuals who may not develop significant lung disease or in whom disease will not progress or delaying it in patients who may otherwise rapidly and irreversibly progress. We illustrate this dilemma with five clinical cases: from the case of a patient with normal lung function who requests initiation of therapy to a moderately stable patient without augmentation or a mild patient who, after several years of remaining stable without treatment, deterioration in lung function initiated and, consequently, augmentation therapy was begun. All the nuances associated with the indication of augmentation justify a personalised approach and the decision about initiating augmentation therapy must be made after careful consideration of the pros and cons with the patient in reference centres with experience in treatment. These reference centres can work in collaboration with local hospitals where patients can be closely followed and augmentation therapy can be administered to avoid unnecessary travelling, making periodical administrations more comfortable for the patient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.
- Pneumology Department, Hospital Beatriz Ângelo, Loures, Portugal.
- Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), P. Vall d'Hebron 119-129, Bar…
ORCID-Profile: Marc Miravitlles
Zitieren
APA
Aljama, C., Martin, T., Granados, G., Miravitlles, M., & Barrecheguren, M. (2024). Personalised indication of augmentation therapy for emphysema associated with severe alpha-1 antitrypsin deficiency: a case series. Therapeutic Advances in Respiratory Disease, 18. https://doi.org/10.1177/17534666241271917
Vancouver
Aljama C, Martin T, Granados G, Miravitlles M, Barrecheguren M. Personalised indication of augmentation therapy for emphysema associated with severe alpha-1 antitrypsin deficiency: a case series. Therapeutic Advances in Respiratory Disease. 2024;18. doi:10.1177/17534666241271917
BibTeX
@article{Aljama2024,
author = {Aljama, Cristina and Martin, Teresa and Granados, Galo and Miravitlles, Marc and Barrecheguren, Miriam},
title = {Personalised indication of augmentation therapy for emphysema associated with severe alpha-1 antitrypsin deficiency: a case series},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2024},
volume = {18},
doi = {10.1177/17534666241271917}
}
EUVIMED